About Atomwise
Atomwise is a company based in San Francisco (United States) founded in 2012 by Izhar Wallach. Atomwise has raised $218.64 million across 8 funding rounds from investors including Tencent, Baidu and Khosla Ventures. The company has 70 employees as of December 31, 2023. Atomwise offers products and services including AI Discovery Engine and Pipeline Assets. Atomwise operates in a competitive market with competitors including Relay Therapeutics, Genesis Therapeutics, Unnatural Products, neoX Biotech and BioSymetrics, among others.
- Headquarter San Francisco, United States
- Employees 70 as on 31 Dec, 2023
- Founders Izhar Wallach
-
Sectors
TechnologyHealthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Atomwise Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$218.64 M (USD)
in 8 rounds
-
Latest Funding Round
$44.28 M (USD), Series B
Mar 08, 2024
-
Investors
Tencent
& 17 more
-
Employee Count
70
as on Dec 31, 2023
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Atomwise
Atomwise offers a comprehensive portfolio of products and services, including AI Discovery Engine and Pipeline Assets.
Uses AI to identify new small molecule medicines for development
Facilitates co-developed drug pipelines and partnerships
People of Atomwise
Unlock access to complete
Unlock access to complete
Funding Insights of Atomwise
Atomwise has successfully raised a total of $218.64M across 8 strategic funding rounds. The most recent funding activity was a Series B round of $44.28 million completed in March 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Atomwise
Atomwise has secured backing from 18 investors, including institutional and venture fund investors. Prominent investors backing the company include Tencent, Baidu and Khosla Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity and funds of funds focused on early to mature stage companies and multiple funds
|
Locked | Locked | Locked | |
|
Venture capital firm focused on multiple sectors
|
Locked | Locked | Locked | |
|
Early-stage startups are accelerated via funding and educational programs.
|
Locked | Locked | Locked |
Investor details for Atomwise
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Atomwise
Investment portfolio details for Atomwise
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Atomwise
Detailed financials for Atomwise
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Atomwise Comparisons
Peer comparison for Atomwise
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Atomwise
Atomwise operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Relay Therapeutics, Genesis Therapeutics, Unnatural Products, neoX Biotech and BioSymetrics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Drug discovery platform is developed to study protein motion.
|
|
| Locked | Locked | Locked |
Computational platform for AI-driven small molecule drug discovery is developed.
|
|
| Locked | Locked | Locked |
Peptides are engineered via computational biology for undruggable targets.
|
|
| Locked | Locked | Locked |
Protein-protein interactions are researched and characterized to aid drug discovery.
|
|
| Locked | Locked | Locked |
Provider of a cognitive computing-based biomedical intelligence platform
|
Detailed competitors of Atomwise
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Atomwise
Complete news archive for Atomwise
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Atomwise
Atomwise was founded in 2012 and raised its 1st funding round 1 year after it was founded.
Atomwise is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Atomwise is a funded company, having raised a total of $218.64M across 8 funding rounds to date.
As of Dec 31, 2023, the latest employee count at Atomwise is 70.
Atomwise was founded in 2012 in San Francisco, United States, within the biotechnology sector focused on AI applications. A platform for structure-based drug discovery is offered, leveraging proprietary AtomNet technology. Machine learning is employed by this technology to develop and identify small-molecule drugs according to their structural properties. Operations center on enabling efficient drug candidate screening and optimization for pharmaceutical research.
Atomwise's top competitors include Genesis Therapeutics, Unnatural Products and Relay Therapeutics.
Atomwise offers AI Discovery Engine and Pipeline Assets.
Atomwise has 18 investors. Key investors include Tencent, Baidu, Khosla Ventures, Monsanto, and Gates Foundation.